#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Aplastic anaemia Myelodysplastic syndrome Immunodeficiency Haemophilia A without inhibitors Langerhans' cell histiocytosis Nephroblastoma Oesophageal squamous cell carcinoma stage II Neuroendocrine carcinoma Deafness neurosensory Dementia Alzheimer's type Fibrosarcoma Anti-glomerular basement membrane disease Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndrome Cutaneous calcification Hypophosphatasia More trials…

    Learn about Rare Diseases

    Chondrosarcoma metastatic – Basic Information Pituitary-dependent Cushing’s syndrome – Trials in Disease Kearns-Sayre syndrome – Diagnostics Pemphigoid – Treatment Haemophilia – Diagnostics Rhabdomyosarcoma recurrent Loeys-Dietz syndrome – Treatment Acquired haemophilia Breast angiosarcoma metastatic – Life with Disease Mucous membrane pemphigoid – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Sotalol GSKVX000000048110 Omp10 Vibosameran Lovo-A Ravulizumab Ly3541860 Povidone INSULIN DEGLUDEC Darbepoetin Alfa Pc14586 Deucrictibant Ixekizumab [Al[18F]F]Fapi-74 Dipyridamole SECRETIN SYNTHETIC HUMAN Rasagiline Propofol Aon-D21 Mepivacaine Hydrochloride More therapies…

    Learn about Your Condition

    Lymphangioleiomyomatosis Type 1 diabetes mellitus B-cell lymphoma Systemic infection Malabsorption Idiopathic pulmonary fibrosis Ventricular fibrillation Noonan syndrome Knee arthroplasty Pulmonary fibrosis Vitiligo Mastocytosis Bipolar disorder Dyspnoea Osteochondrodysplasia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Parc Tauli Hospital Universitari

Parc Tauli Hospital Universitari

Parc Del Tauli 1, Sabadell, 08208, Spain

Want to learn more about this study or check if you can participate? Contact us.

  • Efficacy and safety of ontunisertib in patients with fibrostenosing Crohn’s disease: a phase 2b randomized, double‑blind, placebo‑controlled dose‑ranging trial

    Not yet recruiting

    2 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • ORG-129
    Austria Belgium Czechia Denmark France Germany +4

  • A Phase 3 Study of GSK5733584 with drug combination in patients with platinum‑resistant ovarian cancer

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • GSK5733584
    • Bevacizumab
    • Doxorubicin Hydrochloride
    Austria Belgium Czechia Denmark Finland France +7

  • Rinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer

    Not yet recruiting

    3 1 1 1
    Investigated Drugs:
    • HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST FOLR1 CONJUGATED TO 1-[(2R,3R,4R,5S,52S)-1,2,3,4,5-PENTAHYDROXY-52-{[(2S)-1-{[(2S)-5-CARBAMOYLAMINO-1-OXO-1-{3-[({[(1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12HBENZO[DE]PYRANO[3′,4′:6,7]INDOLIZINO[1,2-B]QUINOLIN-1-YL]CARBAMOYL}OXY)METHYL]ANILINO}PENTAN-2-YL]AMINO}-3-METHYL-1-OXOBUTAN-2-YL]CARBAMOYL}-7-[(2S,3R,4R,5R)-2,3,4,5,6-PENTAHYDROXYHEXYL]-46,54-DIOXO10,13,16,19,22,25,28,31,34,37,40,43-DODECAOXA-7,47,53-TRIAZANONAPENTACONTAN-59-YL]-2,5-DIOXOPYRROLIDIN-3-YL
    • Bevacizumab
    • Carboplatin
    Czechia Finland France Germany Greece Hungary +6

  • Short-Acting Pasireotide Test to Predict Treatment Response in Patients with Acromegaly

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    • Pasireotide
    Spain

  • Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Hidradenitis
    Investigated Drugs:
    • Remibrutinib
    Belgium Bulgaria Czechia France Germany Greece +6

  • Daridorexant for Insomnia in Patients with Major Depressive Disorder and Moderate to Severe Insomnia

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Insomnia
    • Major depression
    Investigated Drugs:
    • Cellulose, Microcrystalline
    • Daridorexant
    • Magnesium Stearate
    Spain

  • A study of pembrolizumab, belzutifan, and lenvatinib before main treatment in patients with localized kidney cancer

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    • Belzutifan
    • Lenvatinib
    • Pembrolizumab
    Spain

  • Study to evaluate the effect of upadacitinib on the frequency of eye inflammation in patients with axial spondyloarthritis.

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Axial spondyloarthritis
    Investigated Drugs:
    • Upadacitinib
    Bulgaria France Germany The Netherlands Poland Spain

  • A study to evaluate the long-term safety and effectiveness of sonelokimab in patients with psoriatic arthritis

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Psoriatic arthropathy
    Investigated Drugs:
    • Sonelokimab
    Bulgaria Croatia Czechia Estonia Finland France +10

  • Study of zipalertinib plus chemotherapy versus placebo plus chemotherapy in patients with stage IB-IIIA non-small cell lung cancer with uncommon EGFR mutations after surgery

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Zipalertinib
    • Carboplatin
    • Cisplatin
    Belgium France Germany Greece Italy The Netherlands +3
Previous Page
1 … 9 10 11 12 13 … 29
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!